Ā | DM at baseline | No DM at baseline | DM during FUa | ||||||
---|---|---|---|---|---|---|---|---|---|
All subjects | Never users | Ever users | All subjects | Never users | Ever users | All subjects | Never users | Ever users | |
Nā=ā1034 | Nā=ā512 | Nā=ā522 | Nā=ā8051 | Nā=ā4026 | Nā=ā4025 | Nā=ā761 | Nā=ā269 | Nā=ā492 | |
Females, n (%) | 652 (63.1) | 325 (63.5) | 327 (62.6) | 5600 (69.6) | 2878 (71.5) | 2722 (67.6) | 503 (66.1) | 176 (65.4) | 327 (66.5) |
Age at baseline (years), mean (standard deviation (SD)) | 64.42 (13.0) | 63 13.6) | 65.81 (12.3) | 58.51 (14.7) | 55.94 (14.6) | 61.07 (14.4) | 64.63 (12.8) | 62.4 (12.9) | 65.86 (12.5) |
Body Mass Index in year prior to baseline | |||||||||
āmean (SD) | 29.77 (6.5) | 29.78 (6.7) | 29.77 (6.3) | 27.14 (5.5) | 27.17 (5.5) | 27.1 (5.4) | 29.86 (6.9) | 30.71 (6.8) | 29.35 (6.9) |
āMissing (%) | 180 (17.4) | 87 (17.0) | 93 (17.8) | 3669 (45.6) | 1853 (46.0) | 1816 (45.1) | 224 (29.4) | 68 (25.3) | 156 (31.7) |
Smoking status at baseline, n (%) | |||||||||
āNever smoker | 407 (39.4) | 203 (39.7) | 204 (39.1) | 3337 (41.5) | 1748 (43.4) | 1589 (39.5) | 234 (30.8) | 80 (29.7) | 154 (31.3) |
āEver smoker | 600 (58.0) | 293 (57.2) | 307 (58.8) | 3988 (49.5) | 1949 (48.4) | 2039 (50.7) | 505 (66.4) | 182 (67.7) | 323 (65.7) |
āMissing | 2 (0.2) | 1 (0.2) | 1 (0.2) | 41 (0.5) | 20 (0.5) | 21 (0.5) | 5 (0.7) | 1 (0.4) | 4 (0.8) |
SES quintile at baseline (In subset), n (%) | |||||||||
āFirst (least deprived) | 214 (20.7) | 102 (19.9) | 112 (21.5) | 1830 (22.7) | 910 (22.6) | 920 (22.9) | 165 (21.7) | 60 (22.3) | 105 (21.3) |
āSecond | 224 (21.7) | 98 (19.1) | 126 (24.1) | 1993 (24.8) | 1023 (25.4) | 970 (24.1) | 182 (23.9) | 65 (24.2) | 117 (23.8) |
āThird | 215 (20.8) | 121 (23.6) | 94 (18.0) | 1731 (21.5) | 839 (20.8) | 892 (22.2) | 156 (20.5) | 62 (23.1) | 94 (19.1) |
āFourth | 229 (22.2) | 119 (23.2) | 110 (21.1) | 1470 (18.3) | 741 (18.4) | 729 (18.1) | 161 (21.2) | 49 (18.2) | 112 (22.8) |
āFifth (most deprived) | 150 (14.5) | 71 (13.9) | 79 (15.1) | 986 (12.3) | 493 (12.3) | 493 (12.3) | 92 (12.1) | 32 (11.9) | 60 (12.2) |
āMissing | 2 (0.2) | 1 (0.2) | 1 (0.2) | 41 (0.5) | 20 (0.5) | 21 (0.5) | 6 (0.8) | 1 (0.4) | 5 (1.0) |
Charlson comorbidity index at baseline, mean (SD) | 2.57 (0.8) | 2.48 (0.8) | 2.66 (0.8) | 1.32 (0.7) | 1.23 (0.6) | 1.42 (0.7) | 2.63 (0.8) | 2.39 (0.7) | 2.76 (0.8) |
Prior history of macrovascular diseases, n (%) | 113 (10.9) | 41 (8.0) | 72 (13.8) | 297 (3.7) | 108 (2.7) | 189 (4.7) | 77 (10.1) | 16 (6.0) | 61 (12.4) |
History of GC use in year prior to baseline, n (%) | 325 (31.4) | 42 (8.2) | 283 (54.2) | 1861 (23.1) | 256 (6.4) | 1605 (39.9) | 299 (39.3) | 3 (1.1) | 296 (60.2) |
Duration of diabetes at baseline (yrs) | |||||||||
āMean (SD) | 4.59 (3.7) | 4.88 (3.8) | 4.31 (3.6) | N/A | N/A | N/A | N/A | N/A | N/A |
Number of anti-DM medication prior to baseline | |||||||||
ā0 | 525 (50.8) | 264 (50.6) | 261 (51.0) | N/A | N/A | N/A | N/A | N/A | N/A |
ā1 | 482 (46.6) | 249 (47.7) | 233 (45.5) | N/A | N/A | N/A | N/A | N/A | N/A |
ā2 | 26 (2.5) | 8 (1.5) | 18 (3.5) | N/A | N/A | N/A | N/A | N/A | N/A |
ā3 | 1 (0.1) | 1 (0.2) | 0 (0) | N/A | N/A | N/A | N/A | N/A | N/A |
Prescribed insulin prior to follow-up, n (%) | 155 (15.0) | 86 (16.8) | 69 (13.2) | N/A | N/A | N/A | N/A | N/A | N/A |
DMARDs prescribed during follow-up, n (%) | |||||||||
āMethotrexate | 633 (61.2) | 309 (60.4) | 324 (62.1) | 5012 (62.3) | 2386 (59.3) | 2626 (65.2) | 353 (46.4) | 110 (40.9) | 243 (49.4) |
āHydroxychloroquine | 261 (25.2) | 132 (25.8) | 129 (24.7) | 2304 (28.6) | 1129 (28.0) | 1175 (29.2) | 138 (18.1) | 49 (18.2) | 89 (18.1) |
āSulfasalazine | 372 (36.0) | 171 (33.4) | 201 (38.5) | 3333 (41.4) | 1591 (39.5) | 1742 (43.3) | 207 (27.2) | 80 (29.7) | 127 (25.8) |
āLeflunomide | 75 (7.3) | 28 (5.5) | 47 (9.0) | 719 (8.9) | 264 (6.6) | 455 (11.3) | 57 (7.5) | 13 (4.8) | 44 (8.9) |
āOther | 70 (6.8) | 15 (2.9) | 55 (10.5) | 549 (6.8) | 117 (2.9) | 432 (10.7) | 54 (7.1) | 6 (2.2) | 48 (9.8) |
Average GC dose during follow up, mean (SD) | 4.93 (14.0) | 0 | 9.8 (18.5) | 4.38 (6.3) | 0 | 8.75 (6.4) | 5.02 (6.3) | 0 | 7.77 (6.4) |